[seeNonclinical Toxicology]. However, the overall incidence of new malignancies in the randomized trial was lower on the Xofigo arm compared to placebo (<1% vs. 2%; respectively), but the expected latency period for the development of secondary malignancies exceeds the duration of follow up for ...
However, the overall incidence of new malignancies in the randomized trial was lower on the Xofigo arm compared to placebo (<1% vs 2%; respectively), but the expected latency period for the development of secondary malignancies exceeds the duration of follow-up for patients on the trial ...
产地国家:美国处方药:是所属类别: 1套包装规格: 1套计价单位:套件生产厂家英文名:BAYER PHARMACEUTICALS INC原产地英文商品名:XOFIGO SDV INJ DPSH 1/EA原产地英文药品名:RADIUM RA 223 DICHLORIDE中文参考商品译名:Xofigo注射液 1套件中文参考药品译名:二氯化镭-233简介: 近日,美国食品药品监督管理局(FDA)批准Xofig...
产地国家:瑞士处方药:是所属类别: 6000 kBq/0.6毫升/瓶包装规格: 6000 kBq/0.6毫升/瓶计价单位:套件生产厂家英文名:Bayer (Sc
the median duration of exposure was 41 months (range: 0.1 to 56.5 months) vs. 16.7 months (range 0.3 to 55.8) with placebo. Eighty-eight percent and 86% of patients received the 6 planned cycles of docetaxel, in the NUBEQA with docetaxel arm and placebo with docetaxel arm, respectively. ...